Post by Cognixlab

Why $1B in funding won’t buy you velocity. Boston and NYC biotech are seeing record-breaking capital surges. Yet, walk into any scaling lab in Cambridge or Manhattan, and the sentiment is the same: “We have the money, but things still feel slow.” The reason? Capital solves funding problems, but it was never designed to fix infrastructure. At Cognixlab, we see it constantly: a "faster mess" is still a mess. If you layer AI and headcount on top of a fragmented foundation, you don’t scale—you just compound your operational debt. Read why the next 18 months will separate the companies that simply grow from the ones that actually scale. 👇 Read the full insight #Biotech #LifeSciences #OperationalExcellence #AIStrategy #Cognixlab #BostonBiotech #NYCHealthtech